Approaches that target TGF-β, its receptor molecules, or its signaling pathways directly, or strategies that ablate TGF-β completely, have not been used for patients with dysregulated TGF-β signaling due to serious side effects such as cancer development. Here, TGFB1 is linked to cancer.